Physician profile
Richard Reinking
NPI 1639178403
$1,272.86
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,200 · 2020: $41.61 · 2024: $31.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $31.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $31.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $263.05 | 2019-2020 | |
| Pfizer INC. | $89.25 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.14 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.43 | 2019 | |
| Sanofi-Aventis U.S. LLC | $73.13 | 2019 | |
| Janssen Pharmaceuticals, INC | $73.04 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $69.78 | 2019 | |
| Aytu Biopharma, INC. | $65.80 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.60 | 2019 | |
| Novo Nordisk INC | $43.53 | 2019 | |
| Abbott Laboratories | $36.64 | 2019 | |
| Astellas Pharma US INC | $33.42 | 2019 | |
| Abbvie INC. | $32.53 | 2019 | |
| Amgen INC. | $32.47 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $31.93 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $31.73 | 2024 | Impella |
| Boston Scientific Corporation | $29.58 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $23.46 | 2019 | |
| Allergan, INC. | $22.90 | 2019 | |
| Merck Sharp & Dohme LLC | $22.53 | 2019 | |
| Phadia US INC. | $18.48 | 2019 | |
| Daiichi Sankyo INC. | $17.99 | 2019 | |
| Sanofi Pasteur INC. | $16.94 | 2019 | |
| Radius Health, INC. | $13.34 | 2019 | |
| Genentech USA, INC. | $13.06 | 2019 | |
| Lilly USA, LLC | $11.56 | 2019 | |
| Glaxosmithkline, LLC. | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Reinking listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.